Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)

Launched by YALE UNIVERSITY · May 14, 2020

Keywords

ClinConnect Summary

Cardiovascular disease (CVD) remains the leading cause of death in most developed countries, including the United States. A key risk factor for CVD is an elevation in low-density lipoprotein cholesterol, or LDL-C. Based on favorable results from large clinical trials, guidelines support the use of high intensity statin therapy for the reduction of LDL-C in very high risk patients and addition of non-statin therapies including ezetimibe and PCSK9 inhibitors if the LDL-C remains above 70 mg/dL. However, implementation of these guidelines is poor and there remains substantial underuse of evide...

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Patient Subjects:
• • Adults 18 years of age or greater
• • Currently being seen as an outpatient of Internal Medicine or Cardiology within the Yale New Haven Health System
• • At very high risk for ASCVD, defined by a history of a major ASCVD event, and most recent lipid profile with LDL-C greater than 70 mg/dL, with or without other high-risk features (diabetes, CKD, age \>65 years)
• Exclusion Criteria for Patient Subjects:
• • Heart transplant recipient
• • Left ventricular assist device recipient
• • Hospital inpatient status
• • Pregnancy
• • Have opted out of clinical research in MyChart
• Inclusion Criteria for Provider Subjects:
• • Practicing at an outpatient cardiology or internal medicine practice with the Yale New Haven Health System
• • High frequency of eligible patients seen, based on retrospective review of outpatient records